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Abstract
Introduction: Dual Diagnosis (DD), defined as the co-occurrence 
of a Substance Use Disorder (SUD) and a Severe Mental Illness 
(SMI), is associated with several negative outcomes. Typical 
antipsychotics (TAP) are not of great value for patients with DD as 
they are associated with poorer responses and can worsen SUD. 
Atypical antipsychotics (AAP) offer several advantages compared 
to TAP. In DD, they have been found to be effective in treating both, 
psychiatric symptoms and substance use. The aim of this article is 
to review the use of AAP for treating DD patients.
Methods: A search of MEDLINE, EMBASE and Pubmed was 
performed in order to identify publications that examined the use of 
AAP in the treatment of DD.
Results: The largest number of studies focuse on clozapine, 
with consistently positive data. Data regarding aripiprazole are 
also consistent but less substantial. Olanzapine, risperidone 
and quetiapine have given inconclusive and inconsistent results. 
Finally, there is little use of amisulpride, ziprasidone, paliperidone 
and asenapine or it is has not been documented.
Discussion: Today, there is a consensus on using AAT instead 
of TAP for treating patients with DD. Patients with DD show a 
poorer response to treatment with TAP, and TAP may even worsen 
the addictive behaviour. AAP are as effective as TAP in treating 
psychiatric symptoms, but they are more effective in reducing 
substance use in DD patients. Because with the exception of CLO 
none of the AAP have shown to be superior to the others, when 
choosing between the different AAP agents clinicians should take 
into account other variables such as medical comorbidity, possible 
pharmacological interactions of concomitant treatments and profile 
of side effects. Even though a growing body of evidence suggests 
the beneficial effects of AAP in DD patients, further randomized, 
blinded, controlled trials, with larger sample sizes and longer follow-
ups are needed.
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Introduction
Dual diagnosis (DD) is traditionally defined as the co-occurrence 
of a Substance Use Disorder (SUD) and a Severe Mental Illness (SMI) 
[1]. Although in recent years the concept of DD has been extended 
and it is being used to define the co-occurrence of any mental illness 
and a SUD, in this review we will consider Schizophrenia (SCH) and 
related disorders, as well as Bipolar Disorder (BD) with concomitant 
SUD.
More than 50% of the patients with a psychiatric disorder 
meet DSM-IV criteria for alcohol and/or substance abuse and/
or dependence [2]. The substances more commonly used by these 
patients are alcohol, followed by cannabis and cocaine [3]. Several 
complimentary hypotheses have been used to explain the comorbidity 
between SMI and SUD. Traditionally, the association between SUD 
and SMI was explained with the “self-medication” theory, which 
stated that patients use substances to relieve psychiatric symptoms 
or the side-effects of psychiatric medication [4]. However, in recent 
years, the neurobiological theory proposed by Green et al. (1999) is 
gaining importance in the field of DD. They suggest that there is a 
“reward deficiency syndrome” in people with SMI, so that they have 
a dysfunction in their dopamine (DA)-mediated mesocorticolimbic 
(MCL) reward pathways, and use alcohol and other drugs of abuse in 
order to ameliorate this dysfunction in the brain reward system [5].
Comorbid SUD among patients with SMI is associated with more 
negative outcomes such as more relapses [6], more admissions to 
hospital [7], poor response to treatments [8], non-compliance with 
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the treatment [9], increased rates of suicidal ideation [10], increased 
rates of impulsive and violent behaviours [11], increased rates of 
neurological and psychiatric symptoms [12], and higher incidence of 
poverty, unemployment and social exclusion [13].The demographic 
correlates of substance use are well documented and DD patients tend 
to be younger males, with a lower educational level, a family history of 
SUD, and a comorbid Antisocial Personality Disorder (ASPD) [14].
Typical antipsychotics (TAP), unfortunately, are often not 
of great value for patients with a SMI and a SUD. In fact, a poorer 
response to TAP has been described in patients with a past history 
of SUD [15,16]. In addition, an increase in cigarettes smoked after 
the initiation of haloperidol (HAL) treatment has also been reported 
[17]. Two main hypotheses have been proposed to explain this lack 
of efficacy of TAP in dual diagnosed patients: 1) TAP are associated 
with considerable side effects, such as extra pyramidal side effects 
(EPS) and dysphoria, so that DD patients would “self-medicate” in 
order to ameliorate these symptoms [18-20] and 2) they worsen the 
functioning of DA-mediated MCL brain reward circuits because of a 
potent D2 receptor blockade action [5,21].
Atypical antipsychotics (AAP) offer several advantages over 
TAP: 1) they are effective in treating positive symptoms to the 
same extent as TAP; 2) they are as effective or superior to TAP in 
treating negative symptoms; 3) they exert antidepressant and mood 
stabilization actions; 4) they are effective in treating aggression and 
impulsivity; 5) they exhibit better tolerability, especially in terms of 
decreased EPS, tardive dyskinesia and hyperprolactinemia; 6) they 
diminish suicidality and 7) they are associated with an improvement 
in cognition. Furthermore, they have been reported to obtain some 
advantage in the treatment of SUD probably due to their mechanism 
of action, which includes less DA antagonism and pharmacological 
action on serotonin (5HT), histamine (HIS), and norepinephrine 
(NE) pathways [22,23].
The aim of this article is to review the use of AAP for treating 
DD, in order to critically discuss their effectiveness both in treating 
the psychiatric disorder and treating the SUD, their tolerability and 
their safety.
Methods
A search of MEDLINE, EMBASE and Pubmed (1980-present) 
was performed in order to identify English- and Spanish-language 
publications that examined the use of AAP in the treatment of 
DD. Major search terms included dual diagnosis, schizophrenia, 
schizoaffective disorder, bipolar disorder, SUD, on one hand, and 
atypical antipsychotics, clozapine (CLO), amisulpride (AMS), 
aripiprazole (ARI), asenapine (ASE), olanzapine (OLZ), paliperidone 
(PAL), quetiapine (QUE), risperidone(RIS) and ziprasidone (ZIP), 
on the other hand.
The inclusion criteria were the following: 1) studies that had been 
published in English or Spanish; 2) studies which included a sample 
or subsample of patients with a diagnosis of a Psychotic Spectrum 
Disorder such as Substance Induced Psychosis, Schizophrenia or 
Schizoaffective Disorder, and/or a Bipolar Disorder; 3) studies in 
which the presence of a SUD was specified; and 4) studies in which 
the efficacy and/or safety of the pharmacological intervention 
was described. Studies that did not follow the inclusion criteria 
were excluded. With the exception of reviews, all types of studies, 
regardless of their design, were reviewed and therefore included (case 
reports, case series, retrospective analyses, open, prospective case-
control studies and prospective, randomised, double-blind controlled 
studies).
A careful review of the titles and abstracts of the total number 
of publications found in the literature search using all possible 
combinations of major search terms was carried out. Those studies 
that followed the inclusion criteria were selected and we read through 
the full text of those studies initially chosen. Review papers and the 
references of the selected studies were searched manually to identify 
papers not located in the electronic database search. The final sample 
included: 25 studies on CLO (that have been described in detail in our 
previous work [24]), 20 studies on OLZ, 20 studies on RIS, 11 studies 
on QUE, 6 studies on ARI, 2 studies on AMS and one study on ZIP.
Results
Clozapine
Clozapine (CLO) is the AAP with the greater body of research 
regarding its use as a pharmacological agent for patients with DD. 
Results regarding CLO have been published in a previous work of 
our group [24]. To summarize, several case reports, case series, 
retrospective and prospective studies, comparing CLO to TAP 
or other AAP such as RIS, OLZ and ZIP have suggested that CLO 
may decrease the use of nicotine, alcohol, or other drugs of abuse 
among patients with DD, as well as craving for these drugs. It is 
also associated with an improvement of psychiatric symptoms and 
social functioning. In addition, it has been found that a history of 
SUD does not influence the positive response to CLO. However, 
clinicians are often hesitant to use CLO as a first-line treatment due 
to its undesirable side effects such as the risk for agranulocytosis and 
seizures, and the need for frequent monitoring [24].
Olanzapine
For Olanzapine (OLZ), a search was performed combining all 
possible major search terms: OLZ on one hand, and Dual Diagnosis or 
Psychosis, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder 
and Substance Use Disorder, on the other. Of the total of 411 articles 
identified, 16 were suitable for our review. Four further studies were 
identified after reading through the full text of studies previously 
found. At the end of our search 20 studies met our inclusion criteria 
and were selected for our review.
OLZ is an AAP with a mechanism of action similar to CLO 
that has also shown some promising results when it comes to treat 
patients with a SMI and a comorbid SUD (Table 1).Two of the first 
authors that pointed out the efficacy of OLZ in treating patients with 
a SMI and a concomitant SUD were Noordsy and O´Keefe. They 
found that combining OLZ with case management and psychosocial 
rehabilitation was effective in reducing substance abuse severity by 
up to 20%, as well as improving psychopathology and psychosocial 
functioning, in a 6-month follow-up, naturalistic study which 
included 70 psychotic patients,58 of whom had a diagnosis of SCH 
or Schizoaffective Disorder (SAD), and a comorbid SUD [25]. These 
results were extended by Littrell´s group. They designed a 12-month 
prospective, open-label study in which 30 patients meeting DSM-
IV criteria for SCH (n=22) or SAD (n=8) and comorbid alcohol or 
cocaine dependence were included. At the end of the study, 70% of the 
patients achieved early, full remission and the remaining 30% early, 
partial remission from substance abuse, with 100% showing sustained 
abstinence from cocaine use. In addition, significant improvements 
were described in psychopathology (positive, negative and general 
symptoms), hopefulness and reduction in antipsychotic-related 
side-effects [22]. More recently, a case report showed a reduction in 
cocaine craving and improvements in psychotic symptoms in a male 
patient with SAD who previously failed to improve while treated with 
depot HAL [26].
Comparative studies of OLZ and TAP, however, are inconclusive, 
with some reporting positive results on the use of OLZ for treating 
patients with DD, and others that have failed to find a beneficial 
response to OLZ compared to TAP in DD patients. On one hand, 
positive results have been found in a 6-month follow-up naturalistic 
study in which 104 psychotic outpatients(64with SCH, 26 with SAD 
and 8 with Bipolar Disorder–BD-), 30 of whom had a comorbid 
alcohol abuse and 22 of whom had a drug abuse were switched to 
OLZ (range of dosage 5-40mg/day, mean dosage 15.28mg/day), and 
compared to 49 patients (26 with SCH, 13 with SAD and 6 with BD), 
8 of whom had a comorbid alcohol abuse and 3 of whom had a drug 
abuse, who continued taking TAP. Patients in the OLZ group showed 
significantly greater improvements on the Brief Psychiatric Rating 
Scale(BPRS), in some items of the Mini Psychiatric Rating Scale 
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60 TR-SCH patients, 23 with lifetime SUD
OLZ (10-25mg/d)
Psychopathology (BPRS, CGI, 
SANS)
No differences between patients with and without SUD 
in outcomes evaluated (BRPS, CGI, SANS), thus same 
efficacy of OLZ in patients with additional SUD





OLZ (10mg/d) (n=15) or HAL (10mg/d) (n=10)
Psychopathology (BPRS, CGI)
Side effects (SAS, dose of BIP 
needed)
Comparable reduction of psychopathology, but more 
EPS with HAL





70 PSY patients, 58 with SCH or SAD + SUD
OLZ (dosage N.S.) + Psychosocial RHB
Psychopathology
Substance abuse
Reduction in alcohol and drug use and 
psychopathology




SCH or SAD + AUD or SUD
Alcohol + Cocaine 100%, Cannabis 60%, 
Hallucinogens 10%, Amphetamines 10%
OLZ (10-25mg/d)
Psychopathology (PANSS, HHI, 
service utilization)
Substance abuse (SSAS, UTS, 
BAL)
Safety (BAS, SAS, AIMS) 
70% of the patients achieved abstinence and 30% 
partial substance abuse remission. Improvement of 
psychopathology (p=0.048) and EPS (p<0.01)
Noordsy et al. (2001) 
[27]
n=153
Nat study, switch design
6 months
PSY patients, 29% AA and 21% SA in the OLZ 





Substance use (CMRS item 2)
Significant reduction in alcohol and substance use 
(p<0.001) and improvement in psychopathology 
(p<0.01) and psychosocial functioning (p=0.09)






OLZ (5-20mg/d) (n=2) or HAL (5-10mg/d) (n=2)
Psychopathology
Cocaine use and craving 
Reduction of psychopathology and cocaine use and 
craving with OLZ






Switched to OLZ from depot HAL
Psychopathology
Cocaine use and craving
Improvement in psychopathology and reduction in 
craving and substance use achieving abstinence
Green et al. (2004) [40]
n=262
MC, Pros, DB, RCT
12 weeks
FE-PSY, 37% with lifetime SUD and 7.6% with 
current abuse
Cannabis 28%, Alcohol 21%, Cocaine 6%, 
Hallucinogens 5%, Opioids 1%
OLZ (5-20mg/d, mean dosage 10.2mg/d) or 
HAL (2-20mg/d, mean dosage 4.8mg/d)
Psychopathology (PANSS, 
MADRS, CGI)
Psychosocial and vocational 
functioning
Substance use 
Among the SUD-Group 27% were responders (23% 
OLZvs. 31% HAL) as compared to 35% of non-SUD 
Group (38% OLZvs. 32% HAL)
Patients with comorbid AUD showed poorer response 
to OLZ (27%) than to HAL (9%) (p<0.02)
Higher drop-out rate among SUD patients receiving 
HAL (49%) compared to OLZ (23%) (p<0.04)










93% of the OLZ patients and 79.3% of the HAL patients 
clinically improved at endpoint. These differences were 
not statistically significant (p=0.25). The differences 
of mean change in the SAS significantly favored OLZ 
(p<0.01). The differences of mean change in the BAS 
favored OLZ (p=0.02)






OLZ (5-20mg/d) or HAL (5-20mg/d)




No significant differences in regard to cocaine use 
(UTS), although there was a significant reduction with 
OLZ and a significant increase with HAL of cocaine use 
compared to the amount at baseline (p<0.05). There 
was a significant increase of craving with OLZ (p<0.05). 
No differences in psychopathology were observed











Significant greater reduction of craving in the OLZ 
group (p=0.04). No significant differences in cocaine 
use and psychopathology 




SCH (61%) or SAD (54%) + SUD or AUD
Polyvalent SUD (34%), Alcohol (27%), Cocaine 
(16%), other SUD (21%)
OLZ (2.5-30mg/d, mean dosage 18.7mg/d) 
(n=15) or RIS (n=16) (2-8mg/d, mean dosage 
3.9mg/d) or ZIP (60-160mg/d, mean dosage 
132.8mg/d) (n=10) or TAP depot (n=10)
Retention rate
Success in completing a DD 
Programme
RIS and ZIP had higher rates of retention compared 
to OLZ(p=0.0002 and p=0.004, for RIS and ZIP 
respectively) and TAP (p=0.003 and p=0.03, for RIS 
and ZIP, respectively). There were no significant 
differences in the length of stay were found between 
RIS and ZIP. 88% of RIS patients and 64% of ZIP 
completed the DD program, whereas only 40% of 
patients taking TAP and 33% of patients in the OLZ 
successfully completed the program. This difference in 
successful completion was statistically significant for 
RIS vs. OLZ (p=0.02) and TAP (p=0.017)




Patients on MET or BUP treatment 
SSD + HD 





Patients in the OLZ group remained significantly longer 
in treatment (p=0.001), had a significant superior 
decrease in the SCL-90 score(p=0.001) and more 
negative UTS (p=0.04)






Cannabis (93%), Cocaine (78%), Alcohol (4%)
OLZ (5-20mg/d) or RIS (3-9mg/d)
Psychopathology (PANSS, 
HDRS, CGI)
Substance use and craving 
(MCR, CCR, QSUI, UTS)
Side effects (AIMS, SAS)
Trend for a greater reduction of cocaine positive urines 
and significantly less self-reported days of use (for 
any drug) (p=0.02) in the OLZ group. There was a 
significant reduction in cannabis craving in the RIS 
group, with no modifications in the OLZ group (p=0.04). 
There were no significant differences between groups 
in cocaine craving
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(MPRS) and in the Clinical Global Impression (CGI), and significant 
improvements in both alcohol (p<0.01) and drug (p=0.01) outcomes 
compared to the control group. However, this study was limited 
because the OLZ group and the control group were not comparable 
in terms of the rates of substance use [27]. A wide range of studies 
have focused on the use of OLZ for treating Cocaine Use Disorders 
(COUD), some with positive findings. In a small pilot double-blinded 
trial that included 4 SCH patients with comorbid cocaine abuse, 
who were assigned to receive OLZ (5-20mg/day) (n=2) or HAL (5-
10mg/day) (n=2), OLZ was associated with significant reductions 
in psychopathology and cocaine use and craving [28]. In addition, 
Smelson et al. conducted a 6-week, prospective, double-blind, 
randomized controlled trial using a cue-exposure paradigm, in which 
31 SCH patients with comorbid cocaine dependence were assigned to 
receive OLZ (5-20mg/day) or HAL (5-20mg/day). OLZ was associated 
with a significant reduction in the cue elicited-craving (p=0.04), 
and patients in the OLZ group had lower scores in the Positive 
and Negative Symptoms Scale (PANSS), General Psychopathology 
Subscale scores (p=0.07) and fewer positive urine toxicology screens 
(UTS) (12.5% and 40%, respectively, p=0.20) compared to patients in 
the HAL group, although differences in the two last outcomes were 
not statistically significant [29]. There is also a 4-week, double-blind 
comparison study of OLZ with HAL in the treatment of amphetamine 
psychosis [30]. This study included 58 patients that suffered from an 
amphetamine psychosis episode who were randomly assigned to 
OLZ (n=29) (5-20mg/day) or HAL (n=29) (5-20mg/day). Although 
no significant differences were found in terms of clinical response 
between OLZ and HAL (p=0.25), and both treatments were effective 
since the first week, with 93% of the patients on OLZ vs. 79.3% of 
the patients on HAL showing a clinical improvement at the study 
endpoint, OLZ was superior to HAL in treatment safety with lower 
frequency and severity of EPS [30]. Another group of comorbid 
pathology where OLZ has shown to have a potential beneficial effect 
in terms of increasing retention and negative UTS, and improving 
psychopathology and tolerability, is in patients with a Schizophrenic 
Spectrum Disorder (SSD) and concomitant heroin dependence. In a 
12-week, prospective, observational trial of opioid agonist substitution 
treatment in combination with OLZ (n=35) or HAL (n=26), which 




SCH, 643 with illicit SUD and 789 without illicit 
SUD
Flexible doses of OLZ (mean dosage 20.1mg/
day) (n=330) or QUE (mean dosage 538.9mg/
day) (n=329) or RIS mean dosage 3.9mg/day) 
(n=333) or ZIP (112.8mg/day) (n=183) or TAP 
(n=257)
Discontinuation rate and time to 
discontinuation
Psychopathology (PANSS, CGI, 
episodes of hospitalization)
Among non-users, OLZ was associated with 
significantly lower discontinuation rates and time to 
discontinuation compared to QUE (p<0.001), RIS 
(p=0.01), TAP (p<0.001), but not ZIP. Among illicit-drug 
users, no significant differences between treatment 
groups were found regarding discontinuation rates and 
time to discontinuation. OLZ group was associated 
with a greater psychopathological improvement 
as measured by the PANSS, CGI and number of 
hospitalizations, in both illicit-drug users and non-users, 
compared to the other treatment groups
Van Nimwegen et al. 
(2008) [34]
n=128
MC, Pros, DB, RCT
6 weeks
RO-SCH, 41.3% of whom used cannabis
OLZ (5-20mg/d, mean dosage 11.1mg/d) 
(n=63) or RIS (1-5mg/d, mean dosage 3mg/d) 
(n=65)
Subjective well-being (SWN)
Cannabis craving (OCDUS, 
DDQ)
Similar improvements in subjective well-being were 
found in both groups. Similar decrease in craving for 
cannabis was found in both treatment conditions









Severity of ND and cigarette 
craving (FTQ) 
No significant differences in the degrees of change 
in psychiatric symptoms among the four groups. 
At 8 weeks, HAL was associated with higher EPS 
(p<0.01). HAL was associated with less reduction 
in the severity of ND (p<0.01) and cigarette craving 
(p<0.01) compared to AAP. Among AAP, RIS 
increased cigarette craving (p=0.03), there were no 
significant changes in ND severity and cigarette craving 
associated with OLZ, and ARI showed a reduction in 
both severity of ND and cigarette craving (p<0.01)




FE-SCH (SCH, SCHD, SAD) + CAUD
OLZ (2,5-20mg/d, mean dosage 15mg/d) 





OLZ group did not differ significantly from RIS group in 
initial response rates of positive symptoms and rates 
of cannabis use or alcohol use. Negative symptoms 
(global asociality-anhedonia) improved over time but 
did not differ between groups
Machielsen et al. 
(2012) [36]
n=123
MC, Long, Nat study
6 years
SCH, SCHD, SAD, DED or PDNOS + CAD
CLO (mean dosage 350mg/d) (n=23) or RIS 
(mean dosage 3.46mg/d) (n=48) or OLZ (mean 
dosage 13.78mg/d) (n=52)
Cannabis craving (OCDUS-CAN) There were significant differences in craving between 
RIS and CLO (p=0.001), and between RIS and OLZ 
(p=0.025), in favour of CLO and OLZ, which were 
associated with less craving. No significant differences 
were found between CLO and OLZ




BD, 40 with SUD
Add-on OLZ (5-20mg/d, mean dose 17.31mg/d)
Remission, response and relapse 
rates (YMRS, HDRS, BPRS)
Days of substance abuse (TLFB)
Craving (VAS)
Patients with SUD received significantly higher 
doses of OLZ compared to non-substance abusers. 
Remission, response and relapse rates were similar, 
with mood rating scores dropping significantly from 
baseline to end-point in both groups (p<0.01). In the 
SUD group there was a significant reduction in days of 
substance abuse (p<0.01) and craving (p<0.03) 
AA: Alcohol Abuse, AIMS: Abnormal Involuntary Movement Scale, AMP: Amphetamine, ARI: Aripiprazole, AUD: Alcohol Use Disorders, BAL: Blood Alcohol Levels, 
BAS: Barnes Akathisia Scale, BD: Bipolar Disorder, BIP: Biperiden, BPRS: Brief Psychiatric Rating Scale, BUP: Buprenorphine, CAA: Cannabis abuse, CAD: Cannabis 
Dependence, CAUD: Cannabis Use Disorders, CC: Case-Control, CCR: Cocaine Craving Report, CGI: Clinical Global Impression, CIPD: Cannabis Induced Psychotic 
Disorder, CLO: Clozapine, CMRS: Case Manager Rating Scale, COA: Cocaine Abuse, COD: Cocaine Dependence, DB: Double-blinded, DED: Delusional Disorder, 
DDQ: Drug Desire Questionnaire, EPS: Extrapyramidal symptoms, FE-PSY: First Episode of Psychosis, FTQ: Fagerstrom Tolerance Questionnaire, HAL: Haloperidol, 
HDRS: Hamilton Depression Rating Scale, HD: Heroin Dependence, MADRS: Montgomery-Asberg Depression Rating Scale, MC: Multicenter, MET: Methadone, 
MPRS: Mini Psychiatric Rating Scale, HHI: Herth Hope Index, MCR: Marijuana Craving Report, ND: Nicotine Dependence, NAT: Naturalistic, N.S: Not specified, Obs: 
Observational, OCDUS: Obsessive Compulsive Drug Use Scale, OCDUS-CAN: Obsessive Compulsive Drug Use Scale, cannabis version, OL: Open label, OLZ: 
Olanzapine, PANSS: Positive and Negative Syndrome Scale, PDNOS: Psychotic Disorder NOS, Pros: Prospective, PSY: Psychotic Disorder, QSUIL: Quantitative 
Substance Use Inventory, RCT: Randomized controlled trial, RHB: Rehabilitation, RIS: Risperidone, RO-SCH: Recent Onset Schizophrenia, SA: Substance Abuse, 
SAD: Schizoaffective Disorder, SADS-C+PD: Schedule for Affective Disorders and Schizophrenia- Change Version with psychosis and disorganization items, 
SANS: Scale for the Assessment of Negative Symptoms, SAPS: Scale for the Assessment of Positive Symptoms, SAS: Simpson Angus Scale, SCH: Schizophrenia, 
SCHD: Schizophreniform Disorder, SCL-90-R: Symptoms Checklist 90, SSAS: Schizophrenia/Substance Abuse Schedule, SSD: Schizophrenic Spectrum Disorders, 
SUD: Substance Use Disorder; SUQ: Substance Use Questionnaire, SWN: Subjective Well Being Under Neuroleptics Scale, TAP: Typical Antipsychotics, TLFB: 
Timeline Follow-Back, TR-SCH: Treatment Resistant Schizophrenia, UTS: Urine Toxicological Screens, VAS: Visual Analogue Scale, VCCQ: Voris Cocaine Craving 
Questionnaire, YMRS: Young Mania Rating Scale.
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included 61 patients who met DSM-IV criteria for heroin dependence 
(HD) and the criteria for SSD (SCH, Schizotypal, SAD or BD), OLZ 
was associated with significantly greater rates of retention in treatment 
(p<0.001), greater improvements in psychopathology, measured by 
a decrease in Symptoms Checklist-90 total scores (p<0.001), greater 
rates of early full substance abuse remission and partial substance 
abuse remission achievement (p=0.04), and lesser adverse events [23]. 
On the other hand, despite these positive results, several studies 
have not found statistically significant differences between OLZ and 
TAP in treating patients with a SMI and concomitant SUD. In a 
randomized, double-blind, controlled trial in which 30 patients who 
met DSM-IV criteria for Cannabis Induced Psychotic Disorder (CIPD) 
were randomly allocated to receive either OLZ (10mg/day) (n=15) or 
HAL (10mg/day) (n=15), no significant differences between the two 
groups were found in terms of psychopathology as measured by the 
BPRS (p=0.70) and the CGI (p=0.21), although HAL was associated 
with significantly more EPS, as measured by the Simpson Angus 
Scale (SAS) (p=0.014) and the dose of biperiden used (p=0.027) [31]. 
In addition, in a prospective, double-blind, randomized controlled 
trial with a sample of 24 SCH patients and current COA in the last 6 
months, who were allocated either OLZ (10-20mg/day) or HAL 10-
20mg/day), no significant differences in the proportion of positive 
UTS were found and, unexpectedly, craving for cocaine was rated as 
significantly lower by patients on HAL than those on OLZ (p<0.05). 
OLZ and HAL were equivalent in treating psychotic and depressive 
symptoms and, with exception of abnormal movements, which were 
significantly higher in the HAL group (p<0.05), both treatments were 
equally tolerated [32].
Comparative studies with other AAP have focused nearly 
exclusively on comparing OLZ to RIS, with most studies reporting 
a similar efficacy between both treatments for DD patients [33-35], 
and some finding a beneficial response of OLZ over RIS in treating 
this population [36]. The efficacy of OLZ (5-20mg/day) (n=14) 
and RIS (3-9mg/day) (n=14) was evaluated in a 14-week double 
blind, randomized-controlled study with a sample of 28 patients 
with SCH or SAD and current cocaine and/or marijuana abuse or 
dependence. The study had three phases: a two-week assessment 
phase, a two-week cross-taper phase onto OLZ/RIS, and a ten-week 
period of maintenance on OLZ/RIS. The proportion of positive UTS 
decreased over time for both groups with a trend towards a greater 
reduction for the OLZ group compared to the RIS group. In addition, 
patients in the OLZ group reported, on average, significantly fewer 
days of use than patients in the RIS group (p=0.02). In the last six 
weeks, reductions of cannabis craving were more likely for the RIS 
group compared to the OLZ group (p=0.04), although there was 
no group difference in the proportion of negative cannabis UTSs 
[33]. In addition, van Nimwegen et al. carried out a 6 week, double-
blind randomized trial which included 128 young adults with recent 
onset SCH or related disorders, 41.32% of whom had a comorbid 
cannabis use disorder (CAUD). OLZ and RIS were found to be 
equally effective in terms of improving subjective well-being and 
decreasing cannabis craving [34]. These results were replicated in an 
additional a 16-week, randomized, controlled trial, with a sample of 
49 first-episode patients with a diagnosis of SCH, Schizophreniform 
Disorder (SCHD) or SAD and a co-occurring lifetime diagnosis of 
CAUD, who were assigned to receive treatment either with OLZ 
(n=28) or RIS (n=21). No significant differences were observed in the 
initial response rates of positive and negative symptoms [35]. Finally, 
a multisite, longitudinal, naturalistic cohort study that included 123 
patients who met criteria for a non-affective psychotic disorder and 
a concomitant CAD, found that cannabis craving, assessed with the 
Obsessive Compulsive Drug Use Scale (OCDUS) cannabis specific 
version (OCDUS-CAN), was significantly (p=0.025) less in patients 
treated with OLZ (mean dosage 13.78mg/day) (n=52) compared to 
patients treated with RIS (mean dosage 3.46mg/day) (n=48), with no 
significant differences in cannabis craving compared to CLO (mean 
dosage 350mg/day) (n=23). OLZ was considered an intermediate 
agent between RIS and CLO in treating cannabis craving [36].
However, OLZ has been found to be less effective compared to other 
AAP in two studies [37,38]. Recently, Kim et al. have conducted an 
8-week, prospective trial where OLZ has shown intermediate results 
compared to other AAP. The study included 139 SCH patients with 
comorbid ND who were randomized to receive OLZ (n=32), RIS 
(n=41), ARI (n=31) or HAL (n=35). When analyzing severity of 
ND and cigarette craving, OLZ was not associated with significant 
changes in these two variables, whereas RIS increased cigarette 
craving (p=0.03), and ARI was associated with a reduction in both, 
severity of ND and cigarette craving (p<0-01) [37]. In addition, in 
a retrospective study of 95 patients with schizophrenic spectrum 
disorder and concomitant SUD, OLZ (mean dosage 18.7mg/day) 
(n=15) was associated with a shorter length of stay and lower rates of 
successful treatment completion, similar to TAP (n=10), compared 
to RIS (mean dosage 3.9mg/day) (n=16) and ZIP (mean dosage 
132.8mg/day) (n=15) [38].
Regarding studies that have evaluated how a history of SUD 
influences the response to OLZ, studies are contradictory. On 
one hand, in a 7-week, open label study that included 60 TR-SCH 
patients of whom 23 (38%) had a concomitant history of substance 
abuse, switching to OLZ up to 25mg/day resulted in similar 
outcomes between substance-abusing patients and non-substance 
abusers in the total BPRS, CGI and negative symptoms, as well as 
no increase in side effects, despite the fact that at baseline patients 
who had previously abused substances had lower CGI scores, less 
negative symptomatology and a higher rate of tardive dyskinesia 
[39]. However, on the other hand, Green et al. have reported opposite 
results. They carried out a multicentre, double-blind, controlled 
trial, with a sample of 262 patients with a first-episode SCH, SAD 
or SCHD, 37% of whom had a comorbid lifetime SUD and 7.6% a 
current abuse, being the substances used cannabis (28%), alcohol 
(21%), cocaine (6%), hallucinogens (5%) and opiates (1%). Patients 
were randomized to receive either OLZ (5-20mg/day) or HAL (2-
20mg/day). At 12-week follow-up, 96 patients with a comorbid 
SUD were compared to 166 patients without such comorbidity 
and it was found that among the SUD group, 27% of the patients 
were responders (23% in the OLA and 31% in the HAL group), as 
compared to the 35% of the patients in the non-SUD group (38% for 
OLZ and 32% for HAL), and that AUD status significantly affected 
the probability of a response, with 27% of the patients with alcohol 
use from the HAL group responding to treatment as compared with 
only 9% of the patients of the OLZ group (p<0.02). The authors 
pointed out, nevertheless, that there were significant higher drop-out 
rates in the HAL group for patients with a SUD, so that only 51% 
of the patients in the HAL group completed the study compared 
to 77% of patients in the OLZ group (p<0.04) [40]. In addition, a 
sub-analysis of the Clinical Antipsychotic Trials of Intervention 
effectiveness (CATIE) project, which include 1432 SCH patients, 643 
illicit drug users and 789 non-users, who were randomized to receive 
flexible doses of OLZ (mean dosage 20.1mg/day) (n=330), QUE 
(mean dosage 538.9mg/day) (n=329), RIS mean dosage 3.9mg/day) 
(n=333), ZIP (112.8mg/day) (n=183) and a TAP (n=257) reported 
that among non-users, OLZ was associated with significantly lower 
discontinuation rates and time to discontinuation compared to QUE 
(p<0.001), RIS (p=0.01), TAP (p<0.001), but not ZIP. However, this 
apparent superiority of OLZ over the other treatments was attenuated 
and, in the illicit-drug users group, no significant differences between 
treatment groups were found regarding discontinuation rates and 
time to discontinuation. OLZ group was associated with a greater 
psychopathological improvement as measured by the PANSS, CGI 
and number of hospital admissions, in both illicit-drug users and 
non-users, compared to the other treatment groups. The authors 
concluded that the lesser adherence to OLZ among illicit-drug users 
could be due to idiosyncratic reasons [41].
Only one Italian group has focused on the treatment of patients 
with BD and a concomitant SUD. They carried out an 8-week, 
prospective, observational, case-control study with a sample of 80 
hospitalized patients with a diagnosis of BD and a current manic or 
mixed episode, 40 of whom had a SUD and 40 of whom were non-
substance abusers. They received OLZ (5-20mg/day, mean dose 
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were successfully treated with RIS and exhibited a decrease in alcohol 
consumption [43]. Subsequently, Albanese et al. presented the results 
of a small study in which RIS was given as an adjunctive therapy at a 
dosage ranging from 2 to 8mg/day (mean dosage 3.6mg/day) to 14 
patients with SMI (Major Depression with psychotic symptoms, n=8; 
BD, n=3;Posttraumatic Stress Disorder (PTSD), n=3; SCH, n=1; SAD, 
n=1) and a concomitant SUD (alcohol, n=5; polysubstance, n=3; alcohol 
and cocaine, n=3; cocaine, n=2; opioids, n=1). It was found that 11 out 
of 14 patients exhibited a significant clinical improvement in behaviour 
and symptoms within 4 weeks of the beginning of the treatment [44]. 
In a more recent study by the same author, an open-label, naturalistic 
study in which 16 male patients with cocaine dependence and comorbid 
psychiatric disorder were started on RIS (mean starting dose 2.3mg/
day), it was described that 81% of the patients were rated as improved 
or much improved on the CGI scale, and all patients reported mild or 
no craving at the end of the study [45]. Two-month therapy with RIS 
(8mg/day) was also found to be effective in reducing cocaine craving and 
cocaine use, as well as psychiatric symptoms, after switching from TAP 
in 2 SCH patients with comorbid cocaine dependence [46]. Furthermore, 
RIS was also found to be effective in a case report of a 23-year-old male 
diagnosed with SCH and with a 5-year history of opioids and stimulants 
dependence. He was initially treated with OLZ 20mg/day for a period 
of 6 weeks without a positive response. After being switched to RIS 
4mg/day, psychopathology and substance use subsided, and the patient 
reported diminution of craving and relief from psychopathology-related 
anxiety. This asymptomatic state lasted for the 10 months follow-up [47]. 
A Spanish group conducted a 6-month follow-up study with a sample of 
180 psychotic patients and opioid abuse or dependence. RIS (0.5-12mg/
day) improved disability, psychotic symptoms and tolerability of these 
patients. RIS also reduced the rates of opioid abuse patients from 39% at 
baseline to 18% at month 6 [48]. In addition, another Spanish group has 
reported a significant reduction in the rates of patients abusing cocaine 
(from 98.7% to 17.7%), cannabis (from 52.1% to 27.1%) and alcohol 
(from 68.5% to 33.3%) in a 6-month follow-up, open label, prospective, 
multicenter study with a sample of 146 patients that met criteria for a 
psychotic disorder and stimulants abuse or dependence [49,50].
Two comparative studies with TAP have also found RIS to be 
useful in treating patients with a DD. The first one was a 6-week, 
17.31mg/day) through an add-on method. Although the SUD group 
received significantly higher doses of OLZ compared to the non-
substance abusers (p<0.002), remission, response and relapse rates 
were similar, with mood rating scores dropping significantly from 
baseline to end point in both groups (p<0.001). In addition, in the 
SUD group, there was a significant reduction in days of substance 
abuse (p<0.01) and craving (p<0.03) [42].
To summarize, regarding OLZ´s efficacy in the treatment of DD, 
results are inconsistent and inconclusive. Although most of the studies 
agree on the effectiveness of OLZ for treating psychotic symptoms 
and the only study that has been carried out in bipolar population 
found OLZ to be effective in the treatment of mood symptoms, 
results regarding substance use and craving are contradictory, with 
some studies reporting an improvement in drug use and craving 
parameters, and others that do not find significant improvements 
or even a worsen in these parameters. In addition, results should 
be interpreted with caution due to methodological issues that are 
described in detail in the discussion section. Regarding safety and 
tolerability, in those studies in which they were explored [21,23,30-
33,35], OLZ demonstrated to be safe in general. Compared to TAP 
and RIS, OLZ was associated with less EPS [21,30-33]. Common side 
effects associated to OLZ were sedation and weight gain [21,23,35], 
although these side effects did not affect retention rates.
Risperidone
Regarding risperidone (RIS), a search was performed combining 
all possible major search terms: RIS on one hand, and Dual Diagnosis 
or Psychosis, Schizophrenia, Schizoaffective Disorder, Bipolar 
Disorder and Substance Use Disorder, on the other. Of the total of 
391 articles identified, 17 were suitable for our review. Three further 
studies were identified after reading through the full text of studies 
previously found. At the end of our search, 20 studies met our 
inclusion criteria and were selected for our review.
Several case reports, case series, open studies and controlled studies 
have evaluated the efficacy of RIS in treating patients with DD (Table 2). 
The first to report on the effectiveness of RIS in treating patients with 
a SMI and concomitant SUD was Huang, who conducted a 3-month 
follow-up study in which 7 patients meeting criteria for SCH and AD 










7 SCH + AD
RIS (dose N.S.)
Alcohol use Reduction in alcohol use





RIS (6mg/d) (n=15) or HAL (10mg/d) (n=15)
Psychopathology (BPRS)
Side effects (EPS)
No differences in the reduction of 
psychopathology, no differences in EPS















7 SCH and SAD + SUD
Alcohol (57%), Cocaine (36%), Opiate (7%), 
polyvalent (21%)
Add-on RIS (2-8mg/d, average 3.6mg/d)
Clinical response
Tolerability
11 of 14 patients showed clinical 
improvement. RIS was well tolerated




PSY + OA or OD
RIS (0.5-12mg/d, average 2.4mg/d)




Improvement in psychopathology and 
reduction in opiate use from 39% to 18%
Reduction in neurological side effects 
(p<0.0001)




PSY + SA or SD 
RIS (N. S. dose)
Psychopathology (BPRS, CGI, DAS)
Side effects (UKU)
Cocaine and cannabis use
Rates of patients using cocaine decreased 
from 89.7% to 17.7% and rates of patients 
using cannabis decreased from 52.1% to 
27.1%, being these differences statistically 
significant (p<0.0001)
Gutierrez et al. (2001) [50]
n=146
Alcohol use Rates of patients using alcohol was 
reduced from 68.5% to 33.3% , being these 
differences statistically significant (p<0.0001)
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Reduction in psychopathology (trend towards 
significance in the PANSS negative ant total 
subscale), of substance use and craving







Cocaine use and craving 
After switching from TAP to RIS there were 
no changes of craving and cocaine use, as 
well as of psychopathology




SCH or SAD + SUD or AUD
Alcohol (78%), Cannabis (51%)
RIS (average 3.9mg/d) (n=8) or CLO (average 
440mg/d) (n=33)
Substance use Significantly more patients stopped SU with 
CLO (54%) than with RIS (12.5%)





LAR (47mg/2 weeks) + RIS (3.4mg/d) (n=57) 






Significantly less drug use (fewer 
positive UTS), greater improvement in 
psychopathology (PANSS), less EPS and 
better compliance with LAR




SCH (61%) or SAD (54%) + SUD or AUD
Polyvalent SUD (34%), Alcohol (27%), 
Cocaine (16%), other SUD (21%)
OLZ (2.5-30mg/d, mean dosage 18.7mg/d) 
(n=15) or RIS (n=16) (2-8mg/d, mean dosage 
3.9mg/d) or ZIP (60-160mg/d, mean dosage 
132.8mg/d) (n=10) or TAP depot (n=10)
Retention rate
Success in completing a DD 
Programme
RIS and ZIP had higher rates of retention 
compared to OLZ (p=0.0002 and p=0.004, 
for RIS and ZIP respectively) and TAP 
(p=0.003 and p=0.03, for RIS and ZIP, 
respectively). No significant differences in 
length of stay were found between RIS and 
ZIP. 88% of RIS patients and 64% of ZIP 
completed the DD program, whereas only 
40% of patients taking TAP and 33% of 
patients in the OLZ successfully completed 
the program. This difference in successful 
completion was statistically significant for 
RIS vs OLZ (p=0.02) and TAP (p=0.017)




DD (N.S.) + COD





81% of the patients improved in the CGI 
scale, 100% of the patients reported mild o 
no craving, 88% completed the programme





Cannabis (93%), Cocaine (78%), Alcohol (4%)
OLZ (5-20mg/d) or RIS (3-9mg/d)
Psychopathology (PANSS, HDRS, 
CGI)
Substance use and craving (MCR, 
CCR, QSUI, UTS)
Side effects (AIMS, SAS)
Trend for a greater reduction of cocaine 
positive urines and significantly less self-
reported days of use (for any drug) (p=0.02) 
in the OLZ group. There was a significant 
reduction in cannabis craving in the RIS 
group, with no modifications in the OLZ 
group (p=0.04). There were no significant 
differences between groups in cocaine 
craving





CLO (mean dosage 423.6mg/d) (n=25) or RIS 
(mean dosage 7.6mg/d) (n=36)
Hospitalization rates
Time to hospitalization
CLO treated patients were readmitted to 
hospital significantly later than the RIS 
treated patients (p=0.045). At the end of the 
study, 75% of the RIS treated patients had 
been admitted to the hospital, compared to 
48% of patients of the CLO treated patients
Van Nimwegen et al. (2008) 
[34]
n=128
MC, Pros, DB, RCT
6 weeks
RO-SCH, 41.3% of whom used cannabis
OLZ (5-20mg/d, mean dosage 11.1mg/d) 
(n=63) or RIS (1-5mg/d, mean dosage 3mg/d) 
(n=65)
Subjective well-being (SWN)
Cannabis craving (OCDUS, DDQ)
Similar improvements in subjective well-
being were found in both groups. Similar 
decrease in craving for cannabis was found 
in both treatment conditions









Severity of ND and cigarette craving 
(FTQ) 
No significant differences in the degrees 
of change in psychiatric symptoms among 
the four groups. At 8 weeks, HAL was 
associated with higher EPS (p<0.01). HAL 
was associated with less reduction in the 
severity of ND (p<0.01) and cigarette craving 
(p<0.01) compared to AAP. Among AAP, RIS 
increased cigarette craving (p=0.03), there 
were no significant changes in ND severity 
and cigarette craving associated with OLZ, 
and ARI showed a reduction in both severity 
of ND and cigarette craving (p<0.01)




FE-SCH (SCH, SCHD, SAD) + CAUD
OLZ (2,5-20mg/d, mean dosage 15mg/d) 
(n=28) or RIS (1-6mg/d, mean dosage 4mg/d) 
(n=21)
Psychopathology (SADS-C+PD, CGI, 
SANS)
Substance Use (SUQ)
OLZ group did not differ significantly from 
RIS group in initial response rates of positive 
symptoms and rates of cannabis use or 
alcohol use. Negative symptoms (global 
asociality-anhedonia) improved over time but 
did not differ between groups
Machielsen et al. (2012) [36]
n=123
MC, Long, Nat study
6 years
SCH, SCHD, SAD, DED or PDNOS + CAD
CLO (mean dosage 350mg/d) (n=23) or RIS 
(mean dosage 3.46mg/d) (n=48) or OLZ 
(mean dosage 13.78mg/d) (n=52)
Cannabis craving (OCDUS-CAN) There were significant differences in craving 
reduction between RIS and CLO (p=0.001), 
and between RIS and OLZ (p=0.025), in 
favour of CLO and OLZ. No significant 
differences were found between CLO and 
OLZ
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open-label, pilot study that compared RIS (up to 6mg/day) (n=8) 
with TAP (n=10) in a sample of 18 withdrawn cocaine-dependent 
SCH patients. It was found that individuals treated with RIS had 
significantly less cue-elicited craving on the intensity (p=0.005) 
and depression (p=0.031) items, and less substance abuse relapse 
(12.5% in the RIS group, 70% in the TAP group, p=0.025) at study 
completion compared to TAP. In addition, they showed a trend 
towards greater reduction in negative (p=0.068) and global (p=0.079) 
symptoms of SCH [51]. The second one was a 6-month follow-up, 
open-label, randomized, controlled study in which 115 patients with 
SCH and SUD were allocated in two treatment groups: Long-acting 
RIS (LAR) (47.2mg per 15 days and 3.4mg/day of oral RIS) (n=57) 
or zuclopenthixol depot (ZUC) (200mg/ 21 days and 15mg/day of 
oral ZUC) (n=58). LAR patients presented significantly fewer positive 
UTS (p=0.005), showed improved scores on the PANSS (p=0.02) 
and had a better compliance with a Substance Abuse Management 
Program (p=0.001) [52]. In addition, when compared to other AAP, 
as said above, RIS (mean dosage 3.9mg/day) (n=16), together with 
ZIP (mean dosage 132.8mg/day) (n=15), was found to be associated 
with a longer length of stay compared to OLZ (mean dosage 18.7mg/
day) (p=0.0002 and p=0.004, for RIS and ZIP respectively) (n=15) 
and TAP (n=10) (p=0.003 and p=0.03, for RIS and ZIP, respectively), 
in a retrospective study of 95 patients with schizophrenic spectrum 
disorder and concomitant SUD. Moreover, RIS and ZIP were 
associated with higher rates of successful treatment completion. 
88% of RIS patients and 64% of ZIP completed the DD program, 
whereas only 40% of patients taking TAP and 33% of patients in 
the OLZ successfully completed the programme. This difference in 
successful completion was statistically significant for RIS vs. OLZ 
(p=0.02) and TAP (p=0.017) [37]. Finally, there is a very recent one-
year follow-up, randomised controlled trial in which 45 patients with 
an amphetamine-induced psychosis were randomly allocated to ARI 
(15mg/day) or RIS (4mg/day) over a period of 6 weeks, where it was 
found that both, ARI and RIS were effective in treating psychotic 
symptoms, although RIS had the greater effect on positive psychotic 
symptoms (p<0.001), whereas ARI was more effective on treating 
negative symptoms (p=0.08) [53].
Despite these positive findings, other studies have failed to 
find a RIS effective when treating dually diagnosed patients. In a 
randomized, controlled study where 30 patients with cannabis-
induced psychotic disorder were included, no significant differences 
were found in terms of reduction of psychopathology and EPS between 
RIS (6mg/day) (n=15) and HAL (10mg/day) (n=15) [54]. With 
regard to comparison studies with CLO, RIS has failed to show more 
effectiveness when compared to CLO in two studies [55,56]. In the 
first study, RIS (n=8) was found to be less effective than CLO (n=33) 
in a 1-year retrospective survey which included 41 patients with SCH 
or SAD and comorbid alcohol and/or cannabis disorder, in terms of 
achieving abstinence from alcohol and cannabis use. Abstinence rates 
were significantly higher in patients treated with CLO than in those 
treated with RIS (54% vs. 13%, p=0.05) [55]. In addition, in a2-year, 
prospective, naturalistic, observational, community-survival analysis 
study of 61 schizophrenic patients with concomitant AUD, patients 
receiving CLO (n=25) and RIS (n=36) were analyzed, and it was found 
at the end of the study that 75% of the patients treated with CLO were 
readmitted to hospital significantly later than the RIS treated group 
(p=0.045), and that at the end of the study 75% of the RIS treated 
patients had been admitted to the hospital compared to only 48% 
of the CLO treated patients [56]. Finally, a multisite, longitudinal, 
naturalistic cohort study that included 123 patients who met criteria 
for a non-affective psychotic disorder and a concomitant CAD, found 
that cannabis craving, assessed with the Obsessive Compulsive Drug 
Use Scale (OCDUS) cannabis specific version (OCDUS-CAN),was 
significantly (p=0.001) lesser in patients treated with CLO (mean 
dosage 350mg/day) (n=23) compared to patients treated with RIS 
(mean dosage 3.46mg/day) (n=48) [36]. When compared to OLZ, 
some studies have found similar efficacy in several variables such as 
psychotic symptoms and substance use [35] and subjective well-being 
and cannabis craving [34], but there are several studies that have 
reported an increase in cannabis [33,36] and cigarette [37] craving, 
compared to OLZ [33,36,37] or ARI [37].
To sum up, studies involving RIS must be interpreted with caution 
because again, results are inconclusive. Although the majority of case 
reports, open studies and comparative studies with TAP agree on the 
effectiveness of RIS in treating psychotic symptoms in DD patients, 
RIS does not seem to offer a great advantage when it is compared to 
other AAP. In fact, in most of the studies in which it is compared 
to other AAP, RIS is not associated with a greater improvement in 
substance use parameters and craving, and sometimes it even worsens 
them. Although further studies are needed, LAR could be a promising 
option for treating DD patients as it has been found to be effective 
in treating psychotic symptoms as well as in improving substance 
use, probably because it increases treatment adherence. Regarding 
safety and tolerability issues, RIS is generally well tolerated according 
to most of the studies [44,45,48-50,52,54]. However, it is sometimes 
more frequently associated to sedation and EPS.
Quetiapine
With regard to quetiapine (QUE), the search performed 
combining all possible major search terms: QUE on one hand, and 
Dual Diagnosis or Psychosis, Schizophrenia, Schizoaffective Disorder, 
Bipolar Disorder and Substance Use Disorder, on the other, identified 
a total of 300 articles, 11 of which were suitable for our review. No 
further articles were found after reading through the full text.
QUE has shown promising results in most of the studies published 
to date, mainly in patients with SCH or BD and concomitant 
SUD (Table 3). Several studies have focused on the use of QUE in 
general SUD in DD patients. Weisman et al. reported the case of a 
SCH male with a concurrent alcohol and cocaine abuse who was 
successfully treated with QUE (400mg/day) for more than 5 months 
[57]. Concurrently, a 12-week, open, randomized, pilot study that 
included 24 patients with SMI [BD (n=13), SAD (n=6), SCH (n=3) 
and Major Depressive Disorder (MDD) (n=2)] and comorbid SUD 
[cocaine dependence (n=18), amphetamine dependence (AMD) 
(n=3), cocaine abuse (n=2) and amphetamine abuse (AAM) (n=1)] 





RIS (4mg/d) or ARI (15mg/d)
Psychopathology (SANS, SAPS) SANS and SAPS scores decreased 
significantly in both groups. Mean SAPS 
score reduction was greater in the RIS group 
(p < 0.001). Mean SANS score reduction was 
greater in the ARI group (p = 0.08)
AD: Alcohol Dependence, AIMS: Abnormal involuntary Movement Scale, AMP: Amphetamine, ARI: Aripiprazole, AUD: Alcohol Use Disorder, BPRS: Brief Psychiatric 
Rating Scale, CAA: Cannabis Abuse, CAD: Cannabis Dependence, CAUD: Cannabis Use Disorders, CCR: Cocaine Craving Report, CGI: Clinical Global Impression, 
CIPD: Cannabis Induced Psychotic Disorders, CLO: Clozapine, COD: Cocaine Dependence, CR: Case Report, CS: Case Series, DAS: Depression Anxiety Stress 
Scale, DB: Double Blinded, DED:  Delusional Disorder, DD: Dual Diagnosis, DDQ: Drug Desire Questionnaire, DDSS-SV: Desire to Drink Scale, Spanish Version, 
EPS: Extrapyramidal Side Effects, FE-SCH: First Episode of Schizophrenia, FTQ: Fagerstrom Tolerance Questionnaire, HAL: Haloperidol, LAR: Long-acting RIS, 
MC: Multicenter, MCR: Marijuana Craving Report, ND: Nicotine Dependece, Nat: Naturalistic, N.S.: Not specified, OA: Opioid Abuse, HDRS: Hamilton Depression 
Rating Scale, OCDUS: Obsessive Compulsive Drug Use Scale, OCDUS-CAN: Obsessive Compulsive Drug Use Scale, Cannabis Version, OD: Opioid Dependence, 
OL: Open Label, OLZ: Olanzapine, PANSS: Positive and Negative Symptoms Rating Scale, PDNOS: Psychotic Disorder NOS, PICD: Psychotic Induced Cannabis 
Disorder, Pros: Prospective, PSY: Psychotic Disorder, QSUI: Quantitative Substance Use Inventory, RCT: Randomized Controlled Trial, Ret: Retrospective, RIS: 
Risperidone, RO-SCH: Recent Onset Schizophrenia, SA: Stimulant Abuse, SADS-C+PD: Schedule for Affective Disorders and Schizophrenia- Change Version with 
psychosis and disorganization items, SANS: Scale for the Assessment of Negative Symptoms, SAPS: Scale for the Assessment of Positive Symptoms, SAS: Simpson 
Angus Scale, SD: Stimulant Dependence, SAD: Schizoaffective Disorder, SCH: Schizophrenia, SCHD: Schizophreniform Disorder, SU: Substance Abuse, SUD: 
Substance Use Disorder, SUQ: Substance Use Questionnaire, SWN: Subjective Well-Being Under Neuroleptics scale, TAP: Typical Antipsychotics, UKU: Udvalg für 
Undersogelser, UTS: Urine Toxicological Screenings, VCCQ: Voris Cocaine Craving Questionnaire, ZIP:  Ziprasidone,  ZUC: Zuclopenthixol.
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QUE (mean dosage 229.4mg/d)
Psychopathology (HDRS, YMRS, BPRS)
Cocaine Craving (CQC)
Cocaine use (UTS)
Significant improvement in psychiatric symptoms 
(p<0.01) and cocaine craving (p=0.05). No 









Alcohol and cocaine use
Reduction of psychopathology and improvement of 
social functioning. Reduction in alcohol and cocaine 
use
Brown et al. (2003) 
[58]
n=24
OL, Pros, RCT, switch study
12 weeks
PSY (9 with SCH or SAD) + SUD
Cocaine (69%), Amphetamine (14%)
Non-TAP (n=12), QUE (mean dose 
394mg/d) (n=8/12) or TAP (n=12)
Psychopathology (HDRS, BPRS)
Cocaine craving (CQC)
Cocaine or amphetamines use
(self-reported money spent on substance 
use, UTS)
After discontinuing TAP and switching to QUE there 
was a significant improvement in psychopathology 
(p<0.05) and a significant craving reduction 
(p<0.01),  with no significant differences in the 
amount of drug use 






QUE (mean dosage 239mg/d)
Psychiatric symptoms
(YMRS, HDRS, BPRS)
Alcohol use (alcohol drinks/week, days/
week of alcohol use)
Alcohol craving (VAS)
QUE was associated with significant reductions in 
craving (p=0.02), days/week of alcohol use (p=0.04) 
and psychiatric symptoms (p<0.01). Depressive 
symptoms significantly correlated with craving 
(p=0.029)





SCH (n=4) or BD (n=4) + CAD
QUE (dosage N.S.)
Cannabis use Weekly cannabis use was reduced in 97.3% at the 
end of the study





SSD + SUD 
Cannabis (n=15), alcohol (n=10), other 
psychoactive substances (n=9)
QUE (200-800mg/d)
Drug Use (TLFB, UTS, GGT)
Severity of drug use (AUS, DUS)
Carving (VAS, PACS)
Psychiatric and depressive symptoms 
(PANSS, CDSS)
Cognition (CANTAB)
Overall, severity of SUD improved (p<0.05), fewer 
days/week were spent on SUD. Money/week spent 
on alcohol significantly diminished (p<0.05), but 
money/week spent on cannabis did not diminished 
significantly. Craving for alcohol did not improve 
significantly, but craving for cannabis significantly 
diminished (p<0.05)
There were significant improvements in 
psychopathology (p<0.01) and cognition (p<0.05)
Potvin et al. (2008) 
[60]
n=24
Peripheral ECB No significant changes in ECB levels were observed 
during QUE treatment
Brown et al. (2008) 
[63]
n=115
Pros, R, PC, Add-on study
12 weeks
BD outpatients + AA or AD
QUE (up to 600mg/d) or PLA
Psychiatric symptoms (YMRS, HDRS)
Alcohol use
HDRS scores decreased significantly more in the 
QUE group compared to the PLA group (p<0.05). 
No significant differences were found in the 
decrease of the YMRS scores and in alcohol use





Recently detoxified BD (n=16) and SAD 
(n=2) + AD
QUE (300-800mg/d)
Relapse rate (number of drinking days)
Craving (OCDS, VAS)
Psychopathology (BPRS, HDRS, YMRS, 
CGI)
42.8% of patients remained alcohol free at the end 
of the study. 32.1% relapsed. Significant reductions 
from baseline to exit were observed in craving 
(p<0.005), psychopathology (p<0.0001) and number 
of drinking days/week (p=0.005)





Outpatient BD + AD
Treatment with LIT (n=185) or VAL (n=177) 
+ QUE (300-800mg/d) (n=159) or PLA 
(n=169)
Change in the proportion of heavy 
drinking days (TLFB)
Psychopathology (CGI, HARS)
No significant differences in the proportion of heavy 
drinking days between QUE and PLA. No significant 
differences in improvement in psychopathology




DD (n=26), SCH without SUD (n=23), SUD 
without SCH (n=24)
QUE (mean dosages in the three groups: 
554, 478 and 150mg/d, respectively)
Neurological and psychiatric symptoms 
(PANSS, ESRS, BAS)
Substance use (TLFB, UTS)
DD and SCH patients were receiving significantly 
higher doses of QUE (p=0.0001). DD patients had 
significantly higher parkinsonism (p=0.02) and 
depression (p=0.005). DD patients had significantly 
higher SUD severity compared to SUD patients 
(p<0.001)
AA: Alcohol Abuse, AD: Alcohol Dependence, AUS: Alcohol Use Scale, BAS: Barnes Akathisia Scale, BD: Bipolar Disorder, BPRS: Brief Psychiatric Rating 
Scale, CAD: Cannabis Dependence, CANTAB: Cambridge Neuropsychological Test Automated Battery, CC: Case-Control, CDSS: Calgary Depression Scale for 
Schizophrenia, CGI: Clinical Global Impression, COA: Cocaine Abuse, COD: Cocaine Dependence, CQC: Cocaine Craving Questionnaire, CR: Case Report, DB: 
Double blinded, DD: Dual Diagnosis, DUS: Drug Use Scale, ECB: Endogenous Cannabinoids, ESRS: Extrapyramidal Symptoms Rating Scale, FD: Flexible dose, 
GGT: GammaGlutamyltranpeptidase, HARS: Hamilton Anxiety Rating Scale, HDRS: Hamilton Depression Rating Scale, LIT: Lithium, MC: Multicenter, OCDS: 
Obsessive Compulsive Drinking Scale, OL: Open label, PACS: Penn Alcohol Craving Scale, PANSS: Positive and Negative Symptoms Scale, Pros: Prospective, 
PSY: Psychotic Disorder, QUE: Quetiapine, PLA: Placebo, RCT: Randomized Controlled Trials RPCT: Randomized Placebo Controlled Trials, SAD: Schizoaffective 
Disorder, SCH: Schizophrenia, SSD: Schizophrenic Spectrum Disorders, SUD: Substance Use Disorder, TAP: Typical Antipsychotics, TLFB: Timeline Follow Back, 
UTS: Urine Toxicological Screens, VAL: Valproate, VAS: Visual Analogue scale, YMRS: Young Mania Rating Scale
were randomized to continue taking TAP (n=12) or to discontinue 
TAP (n=12), switching in some cases to QUE (mean dosage 394mg/
day) (n=8). Patients who were switched to QUE had significant 
reductions in drug craving, being this reduction more prominent 
at week 3 (p<0.01). They also showed significant improvements in 
psychopathology (p<0.05) compared with those that continued 
treatment with TAP. However, reduction in craving was not followed 
by a reduction in substance use [58]. In addition, in a 12-week, open-
label trial in which 24 SSD patients with comorbid SUD [cannabis 
(n=15), alcohol (n=10), other psychoactive substances (n=9)], were 
switched to QUE (200-800mg/day, mean dosage 545.8mg/day), it was 
found an overall improvement in the severity of substance abuse, in 
terms of a reduction in positive UTS, plasmatic GGT levels, weekly 
days spent in drug abuse and a decrease in the weekly money spent 
in psychoactive substances. In the case of alcohol, cravings did not 
improve significantly over time, but weekly money spent on alcohol 
significantly diminished (p<0.05). Regarding cannabis, cravings 
significantly diminished during QUE therapy (p<0.05), but not 
money spent per week on cannabis. In addition, cognition (p<0.01), 
psychiatric symptoms (p<0.01) and EPS (p<0.05) significantly 
improved at the end of the study [59]. In a further analysis over 
this sample, there was no significant reduction in endogenous 
cannabonoids levels in this group (its augmentation is thought to 
play an important role in an enhance sensitivity to psychoactive 
substances in patients with schizophrenia) after QUE therapy [60].
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Regarding alcohol, all the studies conducted to date are in BD DD 
patients and most of them have found a positive effect of QUE over 
alcohol outcomes. The first to report on the effectiveness of QUE in 
treating patients with BD and AD were Longoria et al. They carried 
out a 12-week, add-on study which included 17 patients with BP and 
AD. QUE (mean dosage 239mg/day) was found to be effective in 
decreasing craving for alcohol (p=0.02), number of days of alcohol use 
per week (p=0.04) and intensity of psychiatric symptoms (p<0.01). 
However, drinks of alcohol per week did not decline significantly. 
No significant correlations were found between changes in alcohol 
craving or use, and psychiatric symptoms, with the exception of 
depressive symptoms and craving (p=0.029) [61]. Subsequently, an 
Italian group has reported that 43% of 28 DD recently detoxified 
alcoholic patients (BD, n=16; SAD, n=2), remained totally alcohol 
free after 16-weeks of treatment with QUE (300-800mg/day). QUE 
therapy was also associated with significant reductions in the number 
of drinking days per week, alcohol craving and psychiatric symptoms 
intensity (p<0.005). Changes in alcohol withdrawal and craving were 
correlated with psychiatric symptoms, being the highest level of 
correlation for the item of insomnia [62]. More recently, Brown et al. 
reported an improvement in depressive symptoms, but no significant 
effect on improvement in manic symptoms or alcohol consumption 
compared to PLA, following 12 weeks of treatment with QUE (titrated 
to 600mg/day) in a sample of 115 outpatients with BD and AA or 
AD [63]. However, adding QUE (300-800mg/day) to lithium (LIT) 
or valproate (VAL) was not been found to be effective in reducing 
the proportion of heavy drinking days and improving psychiatric 
symptoms in a 12-week, placebo-controlled trial, which included 362 
patients with BD and concomitant AD [64].With regard to cannabis, 
there is only one small, open-label study published to date, where a 6 
month therapy with QUE was associated with a reduction of 97.3% 
of weekly cannabis use in a sample of 8 psychotic patients (SCH, n=4; 
BD, n=4), and CAD [65]. Finally, Brown et al. carried out a 12-week, 
open-label, add-on study, where QUE was associated with significant 
improvements in psychopathology (p<0.01) and craving scores 
(p=0.05), in a sample of 17 outpatients with BD and concomitant 
COD. However, no significant decrease in cocaine use was observed 
in terms of money spent on drugs, days of drug use and negative UTS 
[66].
In the most recent study, a case-control study, conducted in 
DD patients treated with QUE, Zhomitsky et al. compared several 
outcomes in terms of neurological and psychiatric symptoms, as well 
as substance use and severity of addiction, in a sample of patients 
with a DD (SCH and SUD) (n=26), patients with SCH without a 
SUD (n=23) and patients with SUD without SCH (n=24). They 
received QUE for 12 weeks. At the end of the study, SUD patients 
improved significantly more than DD patients in SUD severity 
(p<0.001), although at baseline DD had a lower severity of SUD 
compared to SUD patients (p<0.001). In addition, DD patients had 
significantly more EPS than SCH patients at baseline (p=0.03) and 
significantly more EPS than SUD at endpoint (p=0.02). They had 
also more depressive symptoms at baseline and endpoint (p=0.005), 
and positive symptoms at endpoint (p<0.001), compared to SUD and 
SCH patients [67].
To summarize, although QUE in general has brought promising 
results in the field of the treatment of DD, further studies are 
needed. QUE has shown to be effective for treating psychiatric 
symptoms, specially psychotic and depressive symptoms. It has also 
been reported an improvement in cognition associated to QUE. 
With regard to substance use and craving most of the studies have 
focused in AUD, although there are studies that explore the use of 
QUE in cannabis and cocaine use disorders. QUE has generally been 
associated with improvements in substance use and craving, but this 
fact must be analysed cautiously because there are some studies that 
fail to find a positive effect on these parameters, and QUE has not 
demonstrated to be an effective augmentation strategy when added 
to lithium and/or valproate in DD patients. With regard to safety 
and tolerability issues, the majority of studies conclude that QUE is 
a well-tolerated pharmacological agent [59,62,64,66]. Generally side 
effects are mild and are not associated with the discontinuation of 
QUE treatment. The most frequent side effects associated with QUE 
are sedation, somnolence, dizziness, dry mouth and blurred vision. 
In addition, most of the studies agree on the association of QUE with 
weight gain, although mild. Finally, QUE seems not to increase EPS 
and rather reduce them according to some studies.
Aripiprazole, amisulpride and ziprasidone
Aripiprazole (ARI) is an AAP that acts as a D2 receptor partial 
agonist and has been approved for the treatment of SCH and mania. 
To date, there are only one case report and four studies evaluating 
the effectiveness of ARI in treating DD patients (Table 4). Warsi et 
al. reported the case of a 39 year-old man diagnosed with SCH and 
















Alcohol craving (PCS, SRCS)
ARI was associated with an improvement in psychiatric 
symptoms, cessation of daily alcohol intake and reduction 
in alcohol craving








Cocaine and alcohol craving (UTS, 
BCRS) 
Positive UTS dropped  significantly (p<0.001)
Mean cocaine (p=0.026) and alcohol (p=0.006) craving 
scores significantly declined
Declining psychosis scores were significantly associated 
with declining cocaine and alcohol craving (p<0.01)





BD (n=19) or SAD (n=1) + AD (n=17) 
and/or COUD (n=9)
ARI (up to 30mg/d)
Psychiatric symptoms (YMRS, HDRS, 
BPRS)
Substance craving (VAS)
Substance use (days of use/week, 
money spent on substances/week 
and UTS)
ARI was associated with significant improvements in 
psychiatric symptoms (p<0.05), significant reductions in 
alcohol craving (p=0.003) and money spent on alcohol/
week (p=0.042) and significant reductions in cocaine 
craving (p=0.014). No significant changes were observed 
in days/week of alcohol and cocaine use, and in money 
spent on cocaine/week









Severity of ND and cigarette craving 
(FTQ) 
No significant differences in the degrees of change in 
psychiatric symptoms among the four groups. At 8 weeks, 
HAL was associated with higher EPS (p<0.01).HAL 
was associated with less reduction in the severity of ND 
(p<0.01) and cigarette craving (p<0.01) compared to AAP. 
Among AAP, RIS increased cigarette craving (p=0.03), 
there were no significant changes in ND severity and 
cigarette craving associated with OLZ, and ARI showed 
a reduction in both severity of ND and cigarette craving 
(p<0.01)
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concurrent AD, who was treated with ARI at a dosage of 20mg/day 
during 2 months, and improved in psychiatric symptoms and severity 
of AD, his daily intake of alcohol stopping and his alcohol craving 
being reduced [68]. Regarding the four other studies, the first study 
was an 8-week, prospective, open-label study which included 10 
patients diagnosed with SCH and COD. ARI, given at a maximum 
dose of 15mg/day, was associated with a significant drop in the positive 
UTS (p<0.001) that was evident after 2 weeks of having initiated ARI 
treatment, and a decrease in craving scores for cocaine (p=0.026) 
and alcohol (p=0.006). A reduction in psychotic symptoms was 
correlated with reduced cocaine and alcohol craving (p<0.01) [69]. 
Brown et al. conducted a 12-week, open-label study with a sample 
of 20 antipsychotic-treated patients with BD and SAD and current 
substance abuse, who were switched to ARI using an overlap and 
taper method. ARI was found to be effective in improving psychiatric 
symptoms of mania (p=0.021) and depression (p=0.002). In addition, 
in 17 patients who had a current alcohol dependence, a significant 
reduction in the money spent on alcohol (p=0.042) and alcohol 
craving (p=0.003) was observed. In the case of the 9 patients who 
had cocaine-related disorders, it was found a significant reduction in 
cocaine craving (p=0.014), but no in cocaine use [69]. ARI has also 
found to be effective in reducing the severity of nicotine dependence 
(ND) and cigarette craving (p<0.01) compared to other AAP (OLZ 
and RIS) and TAP, in an 8-week, prospective trial that included 139 
SCH patients with comorbid ND [37]. Very recently, combining 
ARI (10mg/day) with topiramate (TOP) (up to 200mg/day) during 
8 weeks, for treating 20 patients with SAD and concomitant opioid 
dependence undergoing Methadone Maintenance Treatment 
(MMT) (80mg/day), in order to taper MET until suspension at 
week 4 by 3mg/day, was found to be effective in reducing clinical 
symptoms and achieving a rapid tapering off of MMT [71]. Finally, 
as said above, a one-year follow-up, randomised controlled trial 
which included 45 patients with an amphetamine-induced psychosis 
who were randomly allocated to ARI (15mg/day) or RIS (4mg/day) 
over a period of 6 weeks, found ARI and RIS to be equally effective 
in treating psychotic symptoms, although ARI was more effective on 
treating negative symptoms (p=0.08) [55]. ARI has been associated 
only with mild side effects which not caused discontinuation of the 
treatment, such as insomnia, stiffness, tremor, dry mouth, sedation 
and restlessness [70].
Only one case report and a Spanish study have been published 
to date regarding the use of amisulpride (AMS) in DD patients 
(Table 4). The case report was of a 47-year-old SCH male with a 
comorbid severe alcohol dependence who was effectively treated 
when AMS (600mg/day) was added to his treatment with CLO (600-
1200mg/day), improving of his resistant symptoms and his alcohol 
addictive behavior [72]. In addition, an experimental, prospective 
study including 97 outpatients with SUD (alcohol, heroin, cocaine or 
cannabis) that had overcome detoxification, and presented symptoms 
of paranoid ideas, hostility, severe irritating or impulsive behaviors, 
interpersonal sensitivity, and/or hearing or visual hallucinations, 
found that 9 month treatment with AMS standardized in two 
ranges (100-300mg/dayor more than 400mg/day, mean dose 493.5 
± 197.1mg/day) was associated with an overall improvement in 
psychological distress, a decreased in craving and an improvement 
in psychological and social functioning [73]. As described above, in 
regard to ZIP (Table 4), ZIP (mean dosage 132.8mg/day) (n=14) was 
associated with a significant longer length of stay and higher rates of 
successful treatment completion, similar to RIS (mean dosage 3.9mg/
day) (n=16) , compared to OLZ (mean dosage 18.7mg/day) (n=15) 
and TAP (n=10) in a sample of 95 patients with SCH (n=42), SAD 
(n=48) or psychotic disorder NOS (n=5) and concomitant SUD [PSD 
(34%), AD (27%) and COD (16%)] treated in a 90-day, inpatient, 
DD treatment programme [38]. No studies have been identified with 
asenapine and paliperidone.
Conclusions
To date, although DD in clinical settings is the norm and not the 
exception, there is relatively very little research in this field. However, 





SAD + OD + MMT
ARI (10mg/d) + TOP (200mg/d)
Tapering and suppression of MET ARI + TOP was effective to achieve MET suppression 
reducing clinical symptoms






RIS (4mg/d) or ARI (15mg/d)
Psychopathology (SANS, SAPS) SANS and SAPS scores decreased significantly in both 
groups. Mean SAPS score reduction was greater in the 
RIS group (p < 0.001). Mean SANS score reduction was 
greater in the ARI group (p = 0.08)
AMISULPRIDE






CLO (600-1200mg/d) + AMS (600mg/d)
Psychopathology
Alcohol addictive behaviour
CLO + AMS was effective in controlling psychiatric 
symptoms and alcohol addictive behaviour





SUD (alcohol, cannabis, cocaine and 
heroin + psychotic symptoms
AMS in two ranges (100-300mg/D 





Overall improvement in their psychological distress, 
a decrease in carving and an improvement in their 
psychological and psychosocial functioning
ZIPRASIDONE




SCH (61%) or SAD (54%) + SUD or AUD
Polyvalent SUD (34%), Alcohol (27%), 
Cocaine (16%), other SUD (21%)
OLZ (2.5-30mg/d, mean dosage 
18.7mg/d) (n=15) or RIS (n=16) (2-
8mg/d, mean dosage 3.9mg/d) or ZIP 
(60-160mg/d, mean dosage 132.8mg/d) 
(n=10) or TAP depot (n=10)
Retention rate
Success in completing a DD 
Programme
RIS and ZIP had higher rates of retention compared 
to OLZ (p=0.0002 and p=0.004, for RIS and ZIP 
respectively) and TAP (p=0.003 and p=0.03, for RIS and 
ZIP, respectively). No significant differences in length 
of stay were found between RIS and ZIP. 88% of RIS 
patients and 64% of ZIP completed the DD program, 
whereas only 40% of patients taking TAP and 33% of 
patients in the OLZ successfully completed the program. 
This difference in successful completion was statistically 
significant for RIS vs OLZ (p=0.02) and TAP (p=0.017)
AAP: Atypical Antipsychotics, AD: Alcohol Dependence, AIMS: Abnormal Involuntary Movement Scale, AMP: Amphetamine, AMS: Amisulpride, ARI: Aripiprazole, 
BCRS: Brief rating craving scale, BD: Bipolar Disorder, BPRS: Brief Psychiatric Rating Scale, CLO: Clozapine, COD: Cocaine Dependence, COUD: Cocaine Use 
Disorder, CR: Case Report, DB: Double blinded, DD: Dual Diagnosis, EPS: Extrapyramidal Symptoms, FTQ: Fagerstrom Tolerance Questionnaire, HAL: Haloperidol, 
HDRS: Hamilton Depression Rating Scale, MET: Methadone, MMT: Methadone Maintenance Treatment, ND: Nicotine Dependence, OD: Opioid Dependence, OL: 
Open Label, OLZ: Olanzapine, PCS: Pennsylvania Craving Scale, Pros: Prospective, RCT: Randomized Controlled Trial, Ret: Retrospective, RIS: Risperidone, SAD: 
Schizoaffective Disorder, SANS:  Scale for the Assessment of Negative Symptoms, SAPS: Scale for the Assessment of Positive Symptoms, SCH: Schizophrenia, 
SRCS: Self-report Craving Scale, SUD: Substance Use Disorder, TAP: Typical Antipsychotics, TOP: Topiramate, UTS: Urine Toxicological Screens, VAS: Visual 
Analogue Scale, YMRS: Young Mania Rating Scale, ZIP: Ziprasidone
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among the pharmacological agents that have been more widely 
studied we find the group of the antipsychotics. Today, there is a 
consensus in using AAP instead of TAP for treating patients with a 
SMI and a comorbid SUD. This is because it has been reported that 
patients with DD show a generally poorer response to treatment with 
TAP [16]. Studies comparing TAP and AAP in DD patients have 
reported that AAP are as effective as TAP in treating psychiatric 
symptoms, but they offer more effectiveness in reducing substance 
use [74]. However, these results have not always been replicated [75]. 
With regard to AAP, the largest number of studies available is 
for CLO. The data on the beneficial effect of CLO are consistently 
positive, although the lack of prospective, controlled, randomized 
trials limits the conclusions that can be drawn. However, clinicians 
are often hesitant to use CLO as a first-line treatment due to several 
undesirable side effects including the risk for agranulocytosis and 
the consequent need for blood tests [14]. Data regarding ARI are 
also quite consistent but less substantial, as there have not yet been 
a great number of studies carried out in DD patients using this 
pharmacological agent. OLZ, RIS and QUE have given inconclusive 
and discrepant results, with some studies reporting on a beneficial 
effect of these agents for treating patients with a DD, and others that 
have failed to find a positive effect on this population. Finally, the use 
of AMS, ZIP, PAL and ASE is yet poor or not documented.
Despite a growing body of evidence suggesting the beneficial 
effects of AAP in DD patients, interpretation of the published 
literature remains limited due to methodological issues that include 
small sample sizes, short follows-up, low attrition rates and the lack 
of randomized, controlled and blinded methodological designs. This 
is generally due to the specific features of DD patients who are more 
difficult to engage and retain in trials, and associate higher rates of 
treatment non-compliance.
To conclude, to date, when choosing between the different AAP 
agents, clinicians may need to rely on indirect data provided by case 
reports, open label, retrospective and prospective studies such as 
those described in detail throughout this review. Because with the 
exception of CLO none of the AAP have shown to be superior to the 
others, when choosing between the different AAP agents clinicians 
should take into account other variables such as medical comorbidity, 
possible pharmacological interactions of concomitant treatments and 
profile of side effects.
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